10 September 2013, London, Manchester, Munich, Boston, Sydney, Melbourne: College Hill Life Sciences’ clients are again well represented this year in the list of finalists for the Scrip Awards, with Clinigen, e-Therapeutics, Mesoblast, Molecular Partners, Prosensa, Roche, and Vaxxas racking up 10 places on short lists between them, following the entries spearheaded by College Hill.
The shortlisted clients are:
Prosensa Therapeutics, a Dutch biopharmaceutical company focused on rare diseases, has been shortlisted for two awards: for the first time as Management Team of the Year and for the third time for Biotechnology Company of the Year. Earlier this year it was honoured with the Rare Disease Company Award from EURORDIS, whilst in 2012 it won the Emerging Star Award at the European Mediscience Awards and was named a Fierce 15 Biotech Company. In 2011 it was EuropaBio SME Biotech Company of the year. After the award entries closed Prosensa completed a very successful IPO on NASDAQ in July 2013. Prosensa is focusing on rare diseases with an unmet medical need - particularly Duchenne Muscular Dystrophy for which it has an exon-skipping RNA drug in Phase III development, partnered with GSK.
Competition for Financing Deal of the Year will be fierce with Clinigen, e-Therapeutics and Mesoblast all short-listed. e-Therapeutics, a drug discovery and development Company pioneering network pharmacology has been shortlisted for its £40million financing on AIM. Mesoblast, the Australian-based regenerative medicines Company, which was shortlisted last year for Biotechnology Company of the Year, has been shortlisted this year for its equity financing of AUS$170m.
Clinigen winner of the 2013 IPO of the Year M&A Award has been shortlisted for both the Financing Deal of the Year SCRIP Award for its IPO on AIM and also for Licensing Deal of the Year for its deal with Theravance for the commercialisation in Europe of Vibativ (telavancin) for the treatment of nosocomial pneumonia. This year it was also shortlisted for Transaction of the Year and Emerging Company Awards at the European Mediscience Awards, and for Best Newcomer Award at the AIM awards in 2013.
Clinigen will, however, face tough competition in the Licensing Deal of the Year category from Molecular Partners. The Swiss-based Company is shortlisted for its global partnership with Allergan for the development and commercialization of a novel class of targeted protein therapeutics termed DARPins for the treatment of serious ophthalmic diseases.
Vaxxas, the Australian developer of a novel vaccine delivery technology - the Nanopatch™ has made the short list for the Best Partnership Alliance Award for its research collaboration with Merck using the Nanopatch vaccine platform. The deal won them the 2012 Janssen AusBiotech Emerging Company of the Year Award and the BioSpectrum Asia-Pacific Emerging Company of the Year Award. Roche has yet again been shortlisted in this category for its deal with Isis Pharmaceuticals for the development of antisense drugs in Huntington's disease. Roche is also nominated for the Best Advance in an Emerging Market Award for its collaboration with Ascletis for the development of treatment options for Chinese patients with Hepatitis C.
Commenting on the awards Sue Charles, Managing Partner said: "It’s great to see the excellent progress that our clients are making being recognised by being shortlisted for these Awards. We work hard with our clients to both identify opportunities and in crafting submissions, and we will be rooting for them all on the night.”
The Awards are judged by a prestigious panel of 15 independent judges, alongside Scrip Intelligence team. The winners will be announced at the black tie ceremony and dinner to be held at London's Lancaster Hotel on 21 November, which College Hill will be attending. For further information about the Awards please click here.
For further information:
+44 (0)20 7457 2020